Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 25, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Castle Biosciences’ Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal

Castle announced that its chief executive officer Derek Maetzold has been named a 2025 Most Admired CEO by the Houston Business Journal.
July 23, 2025 07:00 ET | Source: Castle Biosciences, Inc.

FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test

Castle announced that its DecisionDx®-Melanoma test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA).
July 17, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company’s Strong Culture

Castle Biosciences announced that it has earned multiple awards through the 2025 Top Workplaces program recognizing its strong company culture.
June 11, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention

Derek Maetzold, CEO of Castle Biosciences, will participate in a panel discussion alongside other industry leaders during BIO 2025.
May 29, 2025 16:30 ET | Source: Castle Biosciences, Inc.

New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes

Castle will present new data aimed at enhancing the clinical management of patients with cutaneous melanoma and uveal melanoma at ASCO 2025.
May 09, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result

Castle presented new data from the first independent validation of the recently published COOG2.1 study by Harbour et al. at ARVO 2025.
May 05, 2025 16:05 ET | Source: Castle Biosciences, Inc.

Castle Biosciences to Acquire Previse

Castle Biosciences, Inc. (Nasdaq: CSTL) has signed a definitive agreement to acquire Capsulomics, Inc., d/b/a Previse.
May 02, 2025 16:30 ET | Source: Castle Biosciences, Inc.

New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer

Castle Biosciences will share new data on its TissueCypher test for patients with Barrett’s esophagus at DDW 2025.
April 30, 2025 17:00 ET | Source: Castle Biosciences, Inc.

New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity

Castle announced the publication of a new study demonstrating DecisionDx-Melanoma outperforms AJCC staging and the CP-GEP test.
April 28, 2025 07:00 ET | Source: Castle Biosciences, Inc.

DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma

Castle announces its achievement of surpassing a significant milestone of 200,000 DecisionDx-Melanoma clinical test orders.

Next Page keyboard_arrow_right